Page last updated: 2024-11-05

homocitric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID28371
CHEBI ID17852
SCHEMBL ID111251
MeSH IDM0090868

Synonyms (13)

Synonym
unii-5883xd8hh4
1,2,4-butanetricarboxylic acid, 2-hydroxy-
5883xd8hh4 ,
CHEBI:17852
2-hydroxybutane-1,2,4-tricarboxylic acid
3562-74-1
homocitric acid
SCHEMBL111251
2-hydroxy-1,2,4-butanetricarboxylic acid
DTXSID10331413
Q10860888
(+/-)-homocitric acid
homocitric acid, (+/-)-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
tricarboxylic acidAn oxoacid containing three carboxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (11.11)18.7374
1990's11 (24.44)18.2507
2000's14 (31.11)29.6817
2010's12 (26.67)24.3611
2020's3 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.54 (24.57)
Research Supply Index3.85 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other45 (97.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]